Valneva SE (VLS.PA)
VLS.PA on Paris Stock Exchange
4.01EUR
23 May 2018
4.01EUR
23 May 2018
Change (% chg)
€-0.05 (-1.23%)
€-0.05 (-1.23%)
Prev Close
€4.07
€4.07
Open
€4.06
€4.06
Day's High
€4.07
€4.07
Day's Low
€3.98
€3.98
Volume
106,512
106,512
Avg. Vol
201,020
201,020
52-wk High
€4.19
€4.19
52-wk Low
€2.64
€2.64
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Mar '18 | 32.08 | 0.020 |
| FY 2017 | Dec '17 | 28.95 | -0.049 |
| Sep '17 | 22.48 | -0.040 | |
| Jun '17 | 25.42 | -0.036 | |
| Mar '17 | 28.44 | -0.022 | |
| FY 2016 | Dec '16 | 26.03 | -0.037 |
| Sep '16 | 18.40 | -0.090 | |
| Jun '16 | 25.89 | -0.460 | |
| Mar '16 | 23.75 | -0.070 |
*Note: Units in Millions ofEuro
**Note: Units in Euro
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Year Ending Dec-18 | 5 | 118.24 | 123.40 | 113.88 | 125.31 |
| Year Ending Dec-19 | 7 | 132.51 | 143.00 | 124.52 | 122.34 |
| Earnings (per share) | |||||
| Year Ending Dec-18 | 6 | -0.03 | 0.15 | -0.16 | 0.06 |
| Year Ending Dec-19 | 6 | 0.05 | 0.17 | -0.09 | 0.03 |
Sales and Profit Figures in Euro (EUR);
Valuation Ratios
Dividends
Growth Rates
Financial Strength
Profitability Ratios
Efficiency
Management Effectiveness
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 20.04 | 45.65 | 55.75 |
| EPS (TTM) % | -132.43 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Valneva SE
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 1.04 | -3.61 | 99 | -- |
| 13 Week | 2.10 | -1.99 | 99 | -- |
| 26 Week | 18.70 | 13.72 | 99 | -- |
| 52 Week | 11.03 | -7.20 | 99 | -- |
| YTD | -5.50 | -14.27 | 99 | -- |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Valneva FY Net Loss Narrows To 11.5 Million Euros
- BRIEF-Valneva Says No Safety Concerns Associated With VLA15 In Any Treatment Group
- BRIEF-Valneva Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate VLA15
- BRIEF-Valneva Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate Vla15
- BRIEF-Valneva Initiates Phase I Clinical Study Of Vaccine Candidate Against Chikungunya
Institutional Holders
| % Shares Owned: | 1.69% |
| # of Holders: | 5 |
| Total Shares Held: | 302,227 |
| 3 Mo. Net Change: | 0 |
| # New Positions: | 0 |
| # Closed Positions: | 0 |
| # Increased Positions: | 0 |
| # Reduced Positions: | 0 |
| # Net Buyers: | 0 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.